Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Influenza

  Free Subscription


04.11.2024

1 Arch Virol
1 Biochem Soc Trans
1 J Gen Virol
3 MMWR Morb Mortal Wkly Rep
1 Pediatrics
1 PLoS Comput Biol
13 PLoS One
2 Proc Natl Acad Sci U S A
8 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Arch Virol

  1. WU YJ, Feng WW, Wu ZL, Zhang YY, et al
    Prim-O-glucosylcimifugin alleviates influenza virus-induced pneumonia in mice by inhibiting the TGF-beta1/PI3KCD/MSK2/RELA signalling pathway.
    Arch Virol. 2024;169:232.
    PubMed         Abstract available


    Biochem Soc Trans

  2. PELLMAN J, Goldstein A, Slabicki M
    Human E3 ubiquitin ligases: accelerators and brakes for SARS-CoV-2 infection.
    Biochem Soc Trans. 2024;52:2009-2021.
    PubMed         Abstract available


    J Gen Virol

  3. SAENKHAM-HUNTSINGER P, Drelich AK, Huang P, Peng BH, et al
    BALB/c mice challenged with SARS-CoV-2 B.1.351 beta variant cause pathophysiological and neurological changes within the lungs and brains.
    J Gen Virol. 2024;105:002039.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  4. SUN J, Zhang Y, Zhou S, Song Y, et al
    Laboratory-Confirmed Influenza Hospitalizations During Pregnancy or the Early Postpartum Period - Suzhou City, Jiangsu Province, China, 2018-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:958-964.
    PubMed         Abstract available

  5. JONES CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, et al
    Routine Vaccination Coverage - Worldwide, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:978-984.
    PubMed         Abstract available

  6. BELL J, Meng L, Barbre K, Wong E, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - National Healthcare Safety Network, United States, 2023-24 Respiratory Virus Season.
    MMWR Morb Mortal Wkly Rep. 2024;73:966-972.
    PubMed         Abstract available


    Pediatrics

  7. DYKSTRA HK, Pilkey D, Tautges J, Schnitzer PG, et al
    Characteristics of Children Ages 1-17 Who Died of COVID-19 in 2020-2022 in the United States.
    Pediatrics. 2024;154.
    PubMed         Abstract available


    PLoS Comput Biol

  8. ANDRONICO A, Paireau J, Cauchemez S
    Integrating information from historical data into mechanistic models for influenza forecasting.
    PLoS Comput Biol. 2024;20:e1012523.
    PubMed         Abstract available


    PLoS One

  9. PANDE S, Shamu S, Abdelhamed A, Munyao Kingoo J, et al
    COVID-19 and Female Genital Mutilation/Cutting and child marriage: An online multi-country cross sectional survey.
    PLoS One. 2024;19:e0304671.
    PubMed         Abstract available

  10. IDEGUCHI S, Miyagi K, Kami W, Tasato D, et al
    Clinical features of and severity risk factors for COVID-19 in adults during the predominance of SARS-CoV-2 XBB variants in Okinawa, Japan.
    PLoS One. 2024;19:e0309808.
    PubMed         Abstract available

  11. TANIGUCHI I
    The SARS-CoV-2 ORF6 protein inhibits nuclear export of mRNA and spliceosomal U snRNA.
    PLoS One. 2024;19:e0312098.
    PubMed         Abstract available

  12. IMAI M, Kawakami F, Uematsu T, Matsumoto T, et al
    SARS-CoV-2 propagation to the TPH2-positive neurons in the ventral tegmental area induces cell death via GSK3beta-dependent accumulation of phosphorylated tau.
    PLoS One. 2024;19:e0312834.
    PubMed         Abstract available

  13. LIU X, Luvsandagva B, Wang D, Zhu S, et al
    Impact of preexisting digestive problems on the gastrointestinal symptoms of patients with omicron variant of SARS-CoV-2 infection.
    PLoS One. 2024;19:e0312545.
    PubMed         Abstract available

  14. ABERA A, Fenta EH, Woldehanna BT, Wolde FB, et al
    Impact of COVID-19 on essential healthcare services in Addis Ababa, Ethiopia: Implications for future pandemics.
    PLoS One. 2024;19:e0308861.
    PubMed         Abstract available

  15. DUESTERWALD L, Nguyen M, Christensen P, Long SW, et al
    Using intrahost single nucleotide variant data to predict SARS-CoV-2 detection cycle threshold values.
    PLoS One. 2024;19:e0312686.
    PubMed         Abstract available

  16. MOATASIM Y, Aboulhoda BE, Gomaa M, El Taweel A, et al
    Genetic and pathogenic potential of highly pathogenic avian influenza H5N8 viruses from live bird markets in Egypt in avian and mammalian models.
    PLoS One. 2024;19:e0312134.
    PubMed         Abstract available

  17. YAMAGUCHI N, Fukumoto T, Imagita H
    Relationship between physical activity and neighborhood environment in preschool children during COVID-19.-A cross-sectional study using 24-hour activity records.
    PLoS One. 2024;19:e0304848.
    PubMed         Abstract available

  18. SORNLORM K, U ES, Laohasiriwong W, Thi WM, et al
    Exploring demographic, healthcare, and socio-economic factors as predictors of COVID-19 incidence rate: A spatial regression analysis.
    PLoS One. 2024;19:e0312717.
    PubMed         Abstract available

  19. ZANIB SA, Zubair T, Ramzan S, Riaz MB, et al
    A conformable fractional finite difference method for modified mathematical modeling of SAR-CoV-2 (COVID-19) disease.
    PLoS One. 2024;19:e0307707.
    PubMed         Abstract available

  20. NAIDU SB, Saigal A, Shah AJ, Ogbonnaya C, et al
    Associations between ethnicity and persistent physical and mental health symptoms experienced as part of ongoing symptomatic COVID-19.
    PLoS One. 2024;19:e0312719.
    PubMed         Abstract available

  21. DEZECACHE G, Chevalere J, Martinelli N, Gil S, et al
    Affiliation in times of pandemics: Determinants and consequences.
    PLoS One. 2024;19:e0306310.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  22. GARAIZAR A, Diaz-Oviedo D, Zablowsky N, Rissanen S, et al
    Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments.
    Proc Natl Acad Sci U S A. 2024;121:e2404555121.
    PubMed         Abstract available

  23. ZHANG H, Wang Z, Nguyen HTT, Cornejo Pontelli M, et al
    Facilitating and restraining virus infection using cell-attachable soluble viral receptors.
    Proc Natl Acad Sci U S A. 2024;121:e2414583121.
    PubMed         Abstract available


    Vaccine

  24. R MUGALI R, Ip H, Zikusooka A, Vong L, et al
    Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
    Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  25. MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
    COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
    Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  26. D'SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al
    Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.
    Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174.
    PubMed         Abstract available

  27. AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al
    The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.
    Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383.
    PubMed         Abstract available

  28. MWAMBA G, Gibson EM, Toko C, Tunda C, et al
    Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.
    Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392.
    PubMed         Abstract available

  29. LEIS AM, Wagner A, Flannery B, Chung JR, et al
    Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.
    Vaccine. 2024;42:126493.
    PubMed         Abstract available

  30. MACINTYRE CR, Akhtar Z, Moa A
    Corrigendum to "Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]".
    Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486.
    PubMed        

  31. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al
    SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.
    Vaccine. 2024;42:126463.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.